These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 9002120)

  • 1. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
    Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
    Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
    Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
    Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
    Schaefer HG; Stass H; Wedgwood J; Hampel B; Fischer C; Kuhlmann J; Schaad UB
    Antimicrob Agents Chemother; 1996 Jan; 40(1):29-34. PubMed ID: 8787874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
    Stockmann C; Sherwin CM; Zobell JT; Young DC; Waters CD; Spigarelli MG; Ampofo K
    Pediatr Pulmonol; 2013 Mar; 48(3):211-20. PubMed ID: 22949224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients.
    Schultz AN; Høiby N; Nielsen XC; Pressler T; Dalhoff K; Duno M; Buchard A; Johansen HK; Wang H; Dalbøge CS
    Pediatr Pulmonol; 2017 Mar; 52(3):319-323. PubMed ID: 28221736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.
    Pedersen SS; Jensen T; Hvidberg EF
    J Antimicrob Chemother; 1987 Oct; 20(4):575-83. PubMed ID: 3479419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.
    Christensson BA; Nilsson-Ehle I; Ljungberg B; Lindblad A; Malmborg AS; Hjelte L; Strandvik B
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2512-7. PubMed ID: 1489195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
    Goldfarb J; Stern RC; Reed MD; Yamashita TS; Myers CM; Blumer JL
    Am J Med; 1987 Apr; 82(4A):174-9. PubMed ID: 3555032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis.
    Smith A; Weber A; Pandher R; Williams-Warren J; Cohen ML; Ramsey B
    Infection; 1997; 25(2):106-8. PubMed ID: 9108186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
    LeBel M
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):316-24. PubMed ID: 1907546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection.
    Strandvik B; Hjelte L; Lindblad A; Ljungberg B; Malmborg AS; Nilsson-Ehle I
    Scand J Infect Dis Suppl; 1989; 60():84-8. PubMed ID: 2756354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Treggiari MM; Retsch-Bogart G; Mayer-Hamblett N; Khan U; Kulich M; Kronmal R; Williams J; Hiatt P; Gibson RL; Spencer T; Orenstein D; Chatfield BA; Froh DK; Burns JL; Rosenfeld M; Ramsey BW;
    Arch Pediatr Adolesc Med; 2011 Sep; 165(9):847-56. PubMed ID: 21893650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of ciprofloxacin in pediatric patients.
    Rajagopalan P; Gastonguay MR
    J Clin Pharmacol; 2003 Jul; 43(7):698-710. PubMed ID: 12856383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration.
    Munoz MJ; Llovería P; Santos MP; Abadía AR; Aramayona JJ; Bregante MA
    Vet Q; 1996 Jun; 18(2):45-8. PubMed ID: 8792592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients.
    Vic P; Ategbo S; Turck D; Husson MO; Tassin E; Loeuille GA; Deschildre A; Druon D; Elian JC; Arrouet-Lagandre C; Farriaux JP
    Eur J Pediatr; 1996 Nov; 155(11):948-53. PubMed ID: 8911895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
    Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
    Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.